Clinicians interviewed in a recent study reported various social determinants of health (SDOH) affecting health outcomes for patients with pulmonary arterial hypertension (PAH), indicating the need to address SDOH in PAH care.
Adding a social worker to clinical staff in specialized pulmonary hypertension centers and integrating screening for social determinants of health (SDOH) to support patient care and improve outcomes was viewed positively by pulmonologists and cardiologists, according to results of a recent survey.
Writing in Pulmonary Circulation, researchers aimed to investigate their perspectives on how (SDOH) impacts patients with pulmonary arterial hypertension (PAH). SDOH are the conditions of a patient’s environment that affect their health risks and outcomes.
Participants in the study reported that various SDoH impacted patient health and expressed support for the implementation of SDoH screening and social workers to optimize care for patients with PAH.
Researchers conducted 30-minute virtual interviews with 17 clinicians (13 pulmonologists and 4 cardiologists) treating an overall average of 321 patients with PAH across 17 pulmonary hypertension (PH) centers across the United States. These patients had a high severity of illness and an average age of 52 years; 73% were women, 61% were White, 34% were unemployed, 23% were retired, and 51% had public health insurance such as Medicaid and Medicare. Researchers also interviewed a patient advocate from the Pulmonary Hypertension Association (PHA).
Interviews consisted of open-ended questions based on Healthy People 2030 SDOH framework. This included asking the clinicians about how factors such as health care access, education, employment, neighborhood, social, and community may impact the health of patients with PAH. Researchers then analyzed transcripts of the interviews for key terms and themes of SDOH.
These physicians demonstrated high awareness of the meaning and nuances of the term SDOH, noting the various nonclinical factors impacting the health of their patients with PAH, including health insurance coverage, socioeconomic status, transportation, employment, education, substandard housing, food insecurity, mental health, health literacy, and social support.
For instance, physicians noted the following:
SDoH was not screened at the centers, and clinicians said mostly relied on patient interactions to get a sense of the social factors that may influence their care. While they were in favor of having a social worker on staff, physicians also noted institutional barriers, such as cost, and integrating findings into the electronic health record.
There were some limitations of this study, including the possibility that only clinicians knowledgeable about SDOH agreed to participate in the study, creating self selection bias, and their answers were subjective. Clinicians may have also prepared for the interview, showing higher awareness of SDOH than they would have had if not participating in the study.
However, the researchers said this to be the first study to assess clinician awareness and knowledge of SDOH affecting patients with PAH. Study findings may aid in informing practice models and health policy that focuses on screening and follow-up for SDOH and providing community referrals to help address these SDOH, the researchers concluded.
Reference
Nadipelli VR, Elwing JM, Oglesby WH, El-Kersh K. Social determinants of health in pulmonary arterial hypertension patients in the United States: clinician perspective and health policy implications. Pulmonary Circulation. 2022;12(3). doi:10.1002/pul2.12111
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More
A Call for Consistent Digital Mobility Measurement Protocols in PAH
October 9th 2024As more researchers utilize digital technology to measure mobility in pulmonary arterial hypertension (PAH), a team calls for consistent protocols to make outcomes as meaningful as possible to patients and clinicians
Read More
Combined Chemotherapy and Immunotherapy Improves Outcomes in PAH
September 27th 2024An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical improvement when chemotherapy and immunotherapy were added to PAH triple therapy.
Read More